To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Avalon Announces Expiration of the Sanofi-Aventis Agreement
Avalon Pharmaceuticals, Inc. has announced the expiration of its agreement with sanofi-aventis. The agreement in December 2003 established a collaboration to utilize molecular cytogenetics to identify and validate oncology targets.
The agreement expired as a result of sanofi- aventis' decision not to advance targets that were a focus of the collaboration for further validation.
"We have appreciated the close collaboration with sanofi-aventis on this program," said Paul Young, Ph.D., Vice President of Research for Avalon.
"While they did not select any targets from this program, we expect to continue validation studies on several of the genes as potential Avalon drug discovery targets."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
